Evidence map›Paper›PMID 40735011›Full record

ReviewThe Journal of clinical and aesthetic dermatology

Recommendations for Topical Corticosteroid Use and the Role of Alternative, Advanced Targeted Topical Treatments in the Treatment of Chronic Inflammatory Skin Diseases.

Douglas DiRuggiero, Jaclyn Agopian, Andrew Baker, Amber Blair, Matthew Brunner, Avery Dinallo, Justin Love, Kristin Rygg, Aaron Sookhoo, Melodie Young and 3 more

Abstract readReview
PubMed Full text at PMC
In one paragraph

Review in The Journal of clinical and aesthetic dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology.The Journal of clinical and aesthetic dermatology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Douglas DiRuggieroDr. DiRuggiero is with the Skin Cancer and Cosmetic Dermatology Center in Rome, Georgia.
Jaclyn AgopianMs. Agopian is with the American Skin Institute in Sherman Oaks, California.
Andrew BakerMr. Baker is with DOCS Dermatology in Columbus, Ohio.
Amber BlairMs. Blair is with Dermatology Laser and Vein Specialists of the Carolinas, PLLC in Charlotte, North Carolina.
Matthew BrunnerMr. Brunner is with the Elevate-Derm Conference and the Dermatology and Skin Surgery Center P.C. in Stockbridge, Georgia.
Avery DinalloDr. Dinallo is with Mountain Pine Dermatology in Meridian, Idaho.
Justin LoveMr. Love is with the Department of Dermatology at Loma Linda University in Loma Linda, California.
Kristin RyggMs. Rygg is with Apex Dermatology in Littleton, Colorado.
Aaron SookhooMr. Sookhoo is with Suncoast Skin Solutions in Brandon, Florida.
Melodie YoungMs. Young is with Mindful Dermatology and Modern Research Associates in Dallas, Texas.
Robert HighamMr. Higham and Drs. Seal and Hanna are with Arcutis Biotherapeutics Inc. in Westlake Village, California.
Melissa SealMr. Higham and Drs. Seal and Hanna are with Arcutis Biotherapeutics Inc. in Westlake Village, California.
Diane HannaMr. Higham and Drs. Seal and Hanna are with Arcutis Biotherapeutics Inc. in Westlake Village, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safety concerns associated with topical corticosteroids (TCS) have been increasingly recognized and well documented in medical literature for many decades. In response, advanced targeted topical (ATT) therapies have emerged as safer, effective alternatives for managing chronic inflammatory skin diseases. In this review, a group of experienced dermatology nurse practitioners (NPs) and physician assistants/associates (PAs) summarize key consensus statements from a 2025 physician-expert-panel literature review and consensus statement publication addressing the safety and efficacy of TCS and the role of ATT therapies for chronic inflammatory skin diseases. It highlights practical recommendations for incorporating ATT therapies into clinical practice and emphasizes the vital role of NPs and PAs in monitoring cumulative corticosteroid exposure to minimize the risk of both cutaneous and systemic adverse effects associated with TCS use.

Indexed as

advanced targeted topical (ATT) therapiesConsensus statementscutaneous adverse effectsmonitoringsystemic adverse effectstopical corticosteroids (TCS)

Identifiers

PMID40735011
PMCPMC12303372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.